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Effect of the calcimimetic NPS R-467 on furosemide-induced
nephrocalcinosis in the young rat.
Background. Furosemide induces nephrocalcinosis in both
humans and animals. We showed previously that parathyroidec-
tomy protected against the development of furosemide-induced
nephrocalcinosis in young rats, indicating a possible role for
parathyroid hormone (PTH) in its pathogenesis. Calcimimetic
agents such as NPS R-467 are potent and selective agonists at
the calcium-sensing receptor in parathyroid glands and inhibit
PTH secretion.
Methods. To determine whether NPS R-467 could, like
parathyroidectomy, prevent furosemide-induced nephrocalci-
nosis, we studied 35 6-week-old male Sprague-Dawley rats, di-
vided into five groups. Group A served as control, group B
received intraperitoneally furosemide (40 mg/kg), groups C, D,
and E received furosemide and NPS R-467 intraperitoneally at
doses of 10, 20, and 40 lmol/kg, respectively, daily for 8 days.
During the last 3 days, animals were placed in metabolic cages
for measurement of urine output, food, and water intake. Blood
and kidneys were collected on day 8, 60 to 90 minutes after the
last doses. Kidney calcium content was measured and nephro-
calcinosis scoring (0 to 5) was assessed histologically.
Results. Furosemide increased urine output and fluid in-
take, and decreased body weight gain similarly in all groups.
Serum PTH levels (mean ± SD) were significantly higher in
furosemide-treated control animals (276 ± 226 pg/mL vs. 64 ±
21 pg/mL); NPS R-467 induced a dose-dependent decrease in
PTH levels (52 ± 51 pg/mL, 18 ± 7 pg/mL, and 13 ± 3 pg/mL in
groups C, D, and E, respectively). Plasma Ca2+ was slightly, but
significantly lower in all three NPS R-467 treated groups (5.1 ±
0.4 mg/dL, 4.8 ± 0.3 mg/dL, and 4.5 ± 0.3 mg/dL in groups C, D,
and E, respectively) compared to 5.7 ± 0.1 mg/dL and 5.5 ± 0.2
mg/dL in groups A and B, respectively. Furosemide treatment
induced a substantial increase in kidney calcium content (1819
± 664 lg/g dry weight vs. 126 ± 26 lg/g dry weight) and nephro-
calcinosis scoring (5.0 ± 0.0 vs. 0.0 ± 0.0). Treatment with NPS
R-467 ameliorated the furosemide-induced increase in kidney
calcium content (673 ± 312 lg/g, 361 ± 188 lg/g, and 563 ±
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291 lg/g) and nephrocalcinosis scoring (2.2 ± 1.2, 0.7 ± 0.8, and
1.0 ± 1.2) in groups C, D, and E, respectively.
Conclusion. The calcimimetic agent NPS R-467 prevents the
development of hyperparathyroidism and attenuates nephro-
calcinosis in the furosemide-treated young rat.
Nephrocalcinosis has been described frequently in
neonates and infants with chronic lung disease or conges-
tive heart failure receiving furosemide treatment [1–4].
In animal models, the development of nephrocalcinosis
occurs within a few days of furosemide administration
[5]. The pathophysiologic mechanism of furosemide-
induced nephrocalcinosis is unclear. There are reports
of increased plasma parathyroid hormone (PTH) con-
centrations in furosemide-treated humans [6–8]. It was
suggested that urinary loss of calcium due to furosemide
is compensated for by secondary hyperparathyroidism
in order to maintain serum calcium at a normal level.
In a preliminary study we found that nephrocalcinosis
did not occur in parathyroidectomized rats treated with
furosemide [abstract; Alon US, et al, Pediatr Res 39:357A,
1996]. It is thus possible that PTH has at least a permissive
effect in the pathogenesis of furosemide-induced nephro-
calcinosis.
The parathyroid glands and other organs involved in
mineral metabolism like kidney, bone, and intestine ex-
press a cell surface Ca2+ sensing receptor (CaR) that
enables these cells to respond to small changes in the
concentration of extracellular Ca2+ [9, 10]. In the parathy-
roid glands activation of the CaR, a member of G protein-
coupled sensing receptors, results in a decrease of PTH
secretion [9]. A group of newly developed phenylalky-
lamine compounds, termed type II calcimimetics, such as
NPS R-467 and NPS R-568, enhance activation of the
CaR by extracellular Ca2+. These compounds have po-
tent and selective activity at the CaR in the parathyroid
glands and inhibit PTH secretion [11]. In human stud-
ies, calcimimetics are effective in reducing PTH levels
in patients with either primary [12] or secondary hyper-
parathyroidism [13, 14]. In rats with renal insufficiency,
calcimimetics reduced the number of proliferating cells
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Fig. 1. Light microscopy of renal histo-
pathology demonstrating the grading systems
for severity of kidney calcifications. The re-
nal tissue was stained with Alizarin red which
is specific for calcium phosphate. (A) Score
0, no calcifications. (B) Score 1, mild degree.
(C) Score 3, moderate nephrocalcinosis. (D)
Score 5, severe nephrocalcinosis.
and the average cell volume of the parathyroid gland,
demonstrating inhibitory effects on a variety of parathy-
roid cell functions [15, 16]. By lowering PTH levels, cal-
cimimetics may provide a potential therapeutic approach
to the prevention of furosemide-induced nephrocalci-
nosis, if this condition is mediated through secondary
hyperparathyroidism. The current study was undertaken
to determine whether NPS R-467 could protect against
furosemide-induced nephrocalcinosis in rats.
METHODS
Thirty-five 6-week-old male Sprague-Dawley rats,
weighing 120 to 180 g, were used in this study. They
had free access to deionized water and basal rat diet
(Purina 5755M) (Purina Mills, St. Louis, MO, USA) con-
taining 0.6% calcium, 0.4% phosphorus, 0.2% sodium,
0.4% potassium, and 0.06% magnesium. The animals
were randomly assigned to one of five study groups.
Group A served as a control, group B received
furosemide (40 mg/kg, intraperitoneally) in a single daily
dose for 8 days, groups C, D, and E received furosemide
and NPS R-467 (10, 20, and 40 lmol/kg, intraperitoneally,
respectively) for a total of 8 days. NPS R-467 was dis-
solved in 0.9% saline. The animals were injected with
furosemide and NPS R-467 at different sites of the peri-
toneal cavity.
The animals were housed in individual stainless steel
cages for the first 5 days and then were placed in indi-
vidual metabolic cages during the last 3 days. They were
weighed at the beginning of the study, and on days 3, 6,
and 8. The doses of furosemide and NPS R-467 were ad-
justed according to the change in body weight. Over the
last 3 days, food and water intake as well as urine output
were measured daily for each rat. The last 2-day urine
collection was analyzed for creatinine, calcium, phos-
phate (PO4), and magnesium. At the end of the study,
the animals were anesthetized with ketamine (100 mg/kg,
intraperitoneally). Blood was obtained by aortic punc-
ture at 60 to 90 minutes after the last administration of
furosemide and/or NPS R-467, for analysis of pH, ionized
calcium (Ca2+), PO4, creatinine, and PTH. After exsan-
guination, the kidneys were collected. The left kidney was
ashed and the calcium content measured by the modified
technique of Isaac and Johnson as previously described
[17]. The right kidney was fixed with 10% formalin and
stained with Alizarin red, which is specific for calcium
phosphate deposits [18]. The kidney was sectioned and
the magnitude of the calcification was graded histologi-
cally using light microscopy by two investigators masked
to the treatment of each animal, and to each other’s find-
ings. The severity of the calcifications was graded from
0 to 5 with 0 indicating no calcifications and 5 indicating
maximum calcifications (Fig. 1). The average of readings
was used.
Serum PTH concentrations were determined with a
two-site rat PTH immunoradiometric assay (IRMA) kit
(Immutopics, San Clemente, CA, USA). Plasma pH and
Ca2+ concentrations were measured immediately on hep-
arinized whole blood with Easylyte Calcium Na/K/Ca/pH
analyzer (Medica Corp., Bedford, MA, USA). Serum
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Table 1. Baseline body weight, weight gain, food and water intake, and urine output in 6-week-old rats treated with furosemide and NPS R-467
for 8 days
Group A B C D E
Weight day 1 g 155 ± 31 150 ± 17 153 ± 29 156 ± 33 157 ± 27
Weight gain g/week 53 ± 15a,b,c,d 27 ± 12 22 ± 14 21 ± 6 23 ± 8
Urine output mL/100 g/day 4.0 ± 1.5a,b,c,d 13.3 ± 5.1 11.3 ± 4.5 10.5 ± 2.6 13.4 ± 5.9
Water intake mL/100 g/day 14.1 ± 2.5a,b,c,d 22.7 ± 5.6 20.1 ± 7.1 17.8 ± 4.1 21.5 ± 6.8
Food intake g/100 g/day 8.0 ± 1.1 6.9 ± 0.9 6.6 ± 2.0 6.8 ± 1.2 6.6 ± 1.1
Group A, control; group B, furosemide; group C, furosemide plus NPS R-467 10 lmol/kg; group D, furosemide plus NPS R-467 20 lmol/kg; group E, furosemide
plus NPS R-467 lmol/kg. Values are means ± SD (N = 7/group).
aP < 0.05 group A vs. group B; bP < 0.05 group A vs. group C; cP < 0.05 group A vs. group D; dP < 0.05 group A vs. group E.
Table 2. Effects of furosemide and NPS R-467 on blood chemistry values, creatinine clearance and urine chemistries
Group A B C D E
Serum parathyroid hormone pg/mL 64.5 ± 20.9 276.9 ± 225.7a,b,c 51.8 ± 51.2 17.9 ± 7.3 12.7 ± 3.0
Blood mg/dL
Ca2+ 5.7 ± 0. 5.5 ± 0.2b,c 5.1 ± 0.4d 4.8 ± 0.3 4.5 ± 0.3
PO4 8.8 ± 0.6 9.0 ± 0.6 9.9 ± 1.7 8.5 ± 0.9 8.9 ± 1.0
Creatinine 0.45 ± 0.18 0.51 ± 0.08 0.54 ± 0.15 0.55 ± 0.06 0.55 ± 0.06
Urine
Creatinine clearance mL/min/100 g 0.45 ± 0.13 0.39 ± 0.06 0.38 ± 0.09 0.39 ± 0.07 0.37 ± 0.07
Calcium/creatinine mg/mg 0.06 ± 0.05e 0.18 ± 0.05 0.23 ± 0.18 0.17 ± 0.07 0.15 ± 0.03
Calcium mg/day/100 g 0.15 ± 0.14e 0.51 ± 0.14 0.65 ± 0.48 0.50 ± 0.19 0.44 ± 0.11
PO4 mg/day/100 g 8.3 ± 2.1 15.6 ± 11.3 13.5 ± 8.6 11.6 ± 2.6 9.6 ± 1.2
Ca × PO4 mg/dL2 26.3 ± 14.4 68.5 ± 55.9 72.3 ± 47.5 56.3 ± 28.2 37.3 ± 39.4
Magnesium mg/day/100 g 0.84 ± 0.41 1.40 ± 0.69 1.44 ± 1.13 1.49 ± 0.71 0.81 ± 0.45
Group A, control; group B, furosemide; group C, furosemide plus NPS R-467 10 lmol/kg; group D, furosemide plus NPS R-467 20 lmol/kg; group E, furosemide plus
NPS R-467 lmol/kg. Values are means ± SD (N = 7/group).
aP < 0.05 group B vs. group C; bP < 0.05 group B vs. group D; cP < 0.05 group B vs. group E; dP < 0.05) group C vs. group E; eP < 0.05 group A vs. group C.
and/or urine creatinine, calcium, magnesium, and PO4
levels were analyzed using a Cobas Mira Chemistry An-
alyzer (Roche Diagnostics, Basel, Switzerland).
Data are presented as mean ± SD. Multivariate analy-
sis of variance followed by Tukey post hoc range tests and
multiple comparisons were performed for each value of
the five study groups separately. The mean difference was
significant at a P value < 0.05. The protocol was approved
by the Institutional Animal Care and Use Committee,
University of Missouri-Kansas City.
RESULTS
Body weight was similar in all five groups at the be-
ginning of the study. Daily food intake was not different
among the five groups. Furosemide-treated animals had
significantly higher urine output and fluid intake and de-
creased weight gain; treatment with NPS R-467 did not
affect any of these parameters (Table 1). All animals sur-
vived the study without detectable morbidity.
A substantial increase in serum PTH levels occurred
in group B animals receiving furosemide alone (Fig. 2A).
Treatment with NPS R-467 prevented this increase in
PTH levels and, at the higher doses, suppressed serum
PTH to levels below those in control animals. Furosemide
did not decrease plasma Ca2+ concentrations significantly
but treatment with NPS R-467 was associated with a sig-
nificant dose-related decrease in plasma Ca2+ (Fig. 2B).
In spite of the decrease in Ca2+ concentrations, none of
the NPS R-467-treated animals developed clinical tetany.
There were no differences among the five groups in serum
PO4 and creatinine levels (Table 2).
There were no statistically significant differences in cre-
atinine clearance among the five groups (Table 2). Uri-
nary calcium excretion (urine calcium-to-creatinine ratio
and 24-hour urine calcium content) was higher in all
furosemide-treated groups, although the increase was sig-
nificant only in rats given the lowest dose of NPS R-467.
No differences were noted between the four furosemide-
treated groups (groups B to E). Although urinary PO4,
calcium x PO4 product and magnesium excretion tended
to be higher in furosemide-treated animals, none of the
changes achieved statistical significance. Calcium, PO4,
and magnesium excretion tended to be lowest in rats
given the highest dose of NPS R-467, although none of the
changes were significantly different from those observed
in rats given furosemide alone.
Quantitative analysis and histologic assessment of cal-
cium content of the kidneys demonstrated no calcifi-
cation in control animals but extensive calcification in
rats receiving furosemide alone (Fig. 3). Treatment with
NPS R-467 caused significant decreases in the magni-
tude of furosemide-induced calcium deposition, with the
20 lmol/kg dose of NPS R-467 giving the maximal protec-
tive effect. No further decreases in calcification occurred
with the 40 lmol/kg dose.
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Fig. 2. Effects of furosemide and NPS R-467 on serum parathyroid hor-
mone (PTH) (A) and ionized calcium (B). Values are mean ± SE (N =
7/group). Symbols are: () group A, control; () group B, furosemide;
( ) group C, furosemide plus NPS R-467 10 lmol/kg; ( ) group D,
furosemide plus NPS R-467 20 lmol/kg; ( ) group E, furosemide plus
NPS R-467 40 lmol/kg. a,bP < 0.05 significance of difference from
groups A and B, respectively.
DISCUSSION
The association of furosemide treatment with the de-
velopment of nephrocalcinosis has been demonstrated
in both humans and animals [1, 2, 4, 5] [abstract; Alon
US et al, Pediatr Res 39:357A, 1996] and was confirmed
in this study. The diuretic effect of furosemide in the
present study was evident by the increased urine out-
put, and subsequently high water intake, as well as
decreased weight gain in the treated animals. These
observations confirm the results of our previous exper-
iments in this model of furosemide-induced nephrocal-
cinosis [5, 17] [abstract; Alon US et al, Pediatr Res
39:357A, 1996]. The pathophysiologic mechanism(s) of
furosemide-induced nephrocalcinosis remains obscure.
The hypercalciuric effect of the loop diuretic was pre-
viously mentioned as a major predisposing factor [1, 19].
However, more recent studies demonstrated that the de-
velopment of nephrocalcinosis might not be related to
hypercalciuria [2, 4] and multiple other possible risk fac-
tors of nephrocalcinosis have been reported [20, 21].
Our previous study showed that surgical removal of the
parathyroid glands in the rat protected against the de-
velopment of furosemide-induced nephrocalcinosis [ab-
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Fig. 3 Effects of furosemide and NPS R-467 on kidney calcium con-
tent (A) and nephrocalcinosis scoring (B). Values are mean ± SE (N =
7/group). Symbols are: () group A, control; () group B, furosemide;
( ) group C, furosemide plus NPS R-467 10 lmol/kg; ( ) group D,
furosemide plus NPS R-467 20 lmol/kg; ( ) group E, furosemide plus
NPS R-467 40 lmol/kg. a,bP < 0.05 significance of difference from
groups A and B, respectively. In (B), calcification score in group A
was zero.
stract; Alon US et al, Pediatr Res 39:357A, 1996]. This ob-
servation indicates that PTH plays at least a permissive
role in the pathogenesis of furosemide-induced nephro-
calcinosis. Furosemide reduces calcium reabsorption in
the thick ascending limb (TAL) of Henle loop resulting
in an increased intraluminal calcium load in the distal con-
voluted tubule, which is one of the major sites of action
of PTH on renal calcium reabsorption [22]. In this study,
serum PTH levels were markedly elevated in furosemide-
treated animals, possibly the result of increased urinary
calcium losses. Thus, the development of nephrocalci-
nosis in furosemide-treated animals and humans might
be a consequence of markedly elevated rates of calcium
reabsorption in the distal convoluted tubule, a result of
elevated PTH levels and increased luminal calcium load.
Calcimimetic compounds related to NPS R-467 have
been developed to provide an alternative treatment for
primary and secondary hyperparathyroidism. These com-
pounds potentiate the effects of extracellular Ca2+ at the
CaR, resulting in suppression of PTH secretion [23]. Our
present study confirmed the dose-related inhibitory ef-
fect of the NPS R-467 on PTH secretion. As expected,
the suppression of PTH was associated with a tendency
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for decreased losses of PO4 in the urine in NPS R-467
treated animals.
In parallel with the decrease in serum PTH, a dose-
related decrease in serum Ca2+ was observed in rats
treated with NPS R-467. In the kidney, the Ca2+ sens-
ing receptor is expressed in numerous sites along the
nephron, including the apical membrane of proximal
tubule, the basolateral membrane of TAL of Henle’s loop
and distal convoluted tubule, and the apical membrane of
the inner medullary collecting duct [24]. Activation of the
CaR in cortical TAL increases arachidonic acid formation
by activating phospholipase A2. The active metabolite of
arachidonic acid inhibits the K+ channel and perhaps Na-
K-2Cl cotransporter at the apical membrane [25]. As a
result, Ca2+ and Mg2+ reabsorption through the para-
cellular pathway is decreased due to decreased lumen-
positive transepithelial potential. Nevertheless, it has
been reported in animal studies that the hypocalcemic
response might not be a result of an effect of calcimimet-
ics on the Ca2+ sensing receptor in the kidney [26, 27].
Indeed, the addition of NPS R-467 in groups C to E did
not enhance calciuria in comparison to our group B ani-
mals (Table 2), probably due to the lowered serum Ca2+
concentration in the NPS R-467–treated groups. Over-
all, the predominant effect of calcimimitics that causes
hypocalcemia is the lowering of plasma PTH level. How-
ever, the hypocalcemic response may be a result of the
acting of the calcimimetic on Ca2+ sensing receptor ex-
pressed on other organs like C cells in the thyroid gland
resulting in an increase of calcitonin secretion [28]. El-
evated calcitonin decreases the osteoclastic activity and
subsequently reduces the efflux of Ca2+ from bone. We
did not measure calcitonin or markers bone turnover in
the present study as the evaluation of the mechanism of
hypocalcemia was beyond its scope. Most important, the
mild hypocalcemia did not result in any apparent adverse
consequences.
The decrease in the magnitude of calcium deposits in
the animals receiving NPS R-467 had a tendency to be
dose-dependent (Table 2) but the protective effect of NPS
R-467 against furosemide-induced nephrocalcinosis was
still incomplete even with the highest dose of the cal-
cimimetic. It could be argued that in the present study al-
though suppressed, PTH was still present, whereas in our
previous study in which nephrocalcinosis was fully abol-
ished, PTH was absent following surgical parathyroidec-
tomy [abstract; Alon US et al, Pediatr Res 39:357A, 1996].
However, it seems even more possible that the reason for
attenuation of nephrocalcinosis in the present study was
due to relatively short-term effect of the calcimimetic.
Fox et al [28] demonstrated that the duration of the PTH
suppression with NPS R-568 was dose-dependent but lim-
ited. The levels of PTH were no longer different from the
controls after 4 hours postdose. NPS R-467 is known to
be even less potent than NPS R-568 on the Ca2+ sens-
ing receptor [11], thus possibly explaining its partial ef-
fect in protecting against nephrocalcinosis in our study.
It is therefore possible that different dosing of NPS R-
467 or use of longer-acting calcimimetics could provide
complete protection against nephrocalcinosis.
The present study did not explore the mechanism
through which PTH promotes calcium deposition in the
kidney. As shown in Table 3, urine calcium, phospho-
rus, magnesium, or calcium x phosporus product could
not explain the effect of PTH on the development of
nephrocalcinosis. It is possible that changes in intratubu-
lar pH caused by the bicarbonaturic effect of PTH, which
render the urine more alkaline could be a contributing
factor [29]. Indeed, in a previous study, acidification of
the urine by feeding rats ammonium chloride, protected
them from developing phosphate-induced nephrocalci-
nosis [abstract; Alon US et al, Pediatr Res 33:351A, 1993].
CONCLUSION
The present study confirmed the role of PTH
in the development of furosemide-induced nephro-
calcinosis in the young rat. Furthermore, we found
that the calcimimetic compound, NPS R-467, pro-
tected against furosemide-induced hyperparathyroidism
and subsequently significantly attenuated furosemide-
induced nephrocalcinosis. Once calcimimetic agents are
approved for use in human beings they may have a role
in protecting the infant treated with furosemide from de-
veloping renal calcifications.
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